Recursion Pharmaceuticals nasdaq Rxrx Shares Rose Post Launch of Lowe Drug Discovery Software

Recursion Pharmaceuticals (NASDAQ: RXRX) Shares Rose Post Launch of LOWE Drug Discovery Software

Recursion Pharmaceuticals (NASDAQ: RXRX) shares rose by over 3% in the extended trading Tuesday after the TechBio company revealed its LOWE drug discovery software at the J.P. Morgan Healthcare Conference.

Recursion (RXRX) showcased LOWE (Large Language Model-Orchestrated Workflow Engine), its latest software that handles complex drug discovery tasks through a natural language interface. LOWE is powered by Recursion’s proprietary biological and chemical data and can orchestrate experiments using Recursion’s automated wet laboratories, unleashing the power of the Recursion Operating System in an easy-to-use tool.

Chris Gibson, Ph.D., Co-founder and CEO of Recursion, expressed the significance of this breakthrough:

“Recursion has spent the last 10 years building one of the world’s largest biological and chemical datasets, along with automated wet-lab and dry-lab tools that empower our scientists to move quickly to decode biology to discover and rapidly advance promising programs.”

He further elaborated,

“For the first time, we’ve taught Large Language Models to use many of Recursion’s tools and data in the same way an expert scientist would, but much more simply and in a more scalable way. LOWE provides an exciting glimpse into what we believe the future of drug discovery will look like – a first step towards the development of autonomous ‘AI scientists’ for therapeutic discovery.”

Chris Gibson introduced LOWE at Recursion’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. On Wednesday, January 10, Recursion Pharmaceuticals (NASDAQ: RXRX) and NVIDIA Corporation (NASDAQ: NVDA) will jointly host an exclusive invite-only event. This event will feature an impressive lineup of speakers, including Jensen Huang (Founder and CEO of NVIDIA), Martin Chavez (Partner and Vice Chairman at Sixth Street Capital and Chairman of Recursion), Aviv Regev (Head and Executive Vice President of Research and Early Development at Genentech), Scott Gottlieb (Senior Fellow at the American Enterprise Institute), and Amy Abernethy (President of Product Development and Chief Medical Officer at Verily). The event will also include additional software demonstrations of LOWE.

LOWE was created at Valence Labs, Recursion’s AI research engine, after Recursion acquired Valence Discovery in May 2023. It is part of Valence’s efforts to push the boundaries of AI-enabled scientific discovery. This encompasses the development of:

  1. Foundation models that accurately represent or simulate the biological and chemical worlds of drug discovery
  2. Inference engines and active learners formulate hypotheses and learn from the results
  3. Orchestration and reasoning systems like LOWE can design and execute experiments for hypothesis testing